Underlying undiagnosed inherited marrow failure syndromes among children with cancer
Fahad Alabbas
Marrow Failure and Myelodysplasia Program, Division of Haematology and Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Division of Haematology and Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorSheila Weitzman
Division of Haematology and Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorRonald Grant
Division of Haematology and Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorEric Bouffet
Division of Haematology and Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorDavid Malkin
Division of Haematology and Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Genetic and Genome Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
Search for more papers by this authorOussama Abla
Division of Haematology and Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorCorresponding Author
Yigal Dror
Marrow Failure and Myelodysplasia Program, Division of Haematology and Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Division of Haematology and Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Genetic and Genome Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
Correspondence
Yigal Dror, Division of Hematology/Oncology, the Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1×8, Canada.
Email: [email protected]
Search for more papers by this authorFahad Alabbas
Marrow Failure and Myelodysplasia Program, Division of Haematology and Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Division of Haematology and Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorSheila Weitzman
Division of Haematology and Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorRonald Grant
Division of Haematology and Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorEric Bouffet
Division of Haematology and Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorDavid Malkin
Division of Haematology and Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Genetic and Genome Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
Search for more papers by this authorOussama Abla
Division of Haematology and Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorCorresponding Author
Yigal Dror
Marrow Failure and Myelodysplasia Program, Division of Haematology and Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Division of Haematology and Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Genetic and Genome Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
Correspondence
Yigal Dror, Division of Hematology/Oncology, the Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1×8, Canada.
Email: [email protected]
Search for more papers by this authorAbstract
To study the prevalence of pediatric cancer patients who have underlying inherited bone marrow failure syndrome (IBMFS), we retrospectively reviewed the medical records of newly diagnosed pediatric cancer patients at The Hospital for Sick Children from June 2009 to May 2010, focusing on clinical, laboratory, and treatment-related findings which may indicate underlying IBMFS. We found five (1.8%) patients out of 276 who had two or more findings suggestive of IBMFS. We conclude that a small fraction of patients with cancer have clinical features that indicate investigations to rule out underlying IBMFSs. A prospective study is needed to determine their prevalence.
REFERENCES
- 1Dror Y. Inherited bone marrow failure disorders. In: EE Churchill Livingstone, ed. Hoffman's Textbook of Hematology: Principles and Practice. 7th ed. 2015. In press.
- 2Dror Y. Genetic basis of inherited bone marrow failure syndromes. In: K Ikehara, ed. Advances in the Study of Genetic Disoders. Rijeka: In Tech Open Access Publishers, Croatia, 2011: 1–37.
10.5772/17388 Google Scholar
- 3Alter BP. Inherited bone marrow failure syndromes. In: DG Nathan, SH Orkin, D Ginsberg, AT Look, eds. Hematology of Infancy and Childhood. Philadelphia: W.B. Saunders; 2003: 280–365.
- 4Tsangaris E, Klaassen R, Fernandez CV, et al. DrorY.Genetic analysis of inherited marrow failure syndromes from one prospective, comprehensive and population-based cohort and identification of novel mutations. J Med Genet. 2011; 48(9): 618.
- 5Cohn MA, D'Andrea AD. Chromatin recruitment of DNA repair proteins: lessons from the Fanconi anemia and double-strand break repair pathways. Mol Cell. 2008; 32(3): 306–312.
- 6Vulliamy TJ, Dokal I. Dyskeratosis congenita: the diverse clinical presentation of mutations in the telomerase complex. Biochimie. 2008; 90: 122–130.
- 7Rujkijyanont P, Watanabe K, Ambekar C, et al. SBDS-deficient cells undergo accelerated apoptosis through the Fas-pathway. Haematologica. 2008; 93(3): 363–371.
- 8Cumming RC, Lightfoot J, Beard K, Youssoufian H, O'Brien PJ, Buchwald M. Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1. Nat Med. 2001; 7: 814–820.
- 9Menne TF, Goyenechea B, Sánchez-Puig N, et al. The Shwachman-Bodian-Diamond syndrome protein mediates translational activation of ribosomes in yeast. Nat Genet. 2007; 39: 486–495.
- 10Choesmel V, Bacqueville D, Rouquette J, et al. Impaired ribosome biogenesis in Diamond-Blackfan anemia. Blood. 2007; 109: 1275–1283.
- 11Ghemlas I, Li H, Zlateska B, Klaassen R, et al. Improving diagnostic precision, care and syndrome definitions using comprehensive next-generation sequencing for the inherited bone marrow failure syndromes. J Med Genet. 2015 Sep; 52(9): 575–584.
- 12Teo JT, Klaassen R, Fernandez CV, et al. Clinical and genetic analysis of unclassifiable inherited bone marrow failure syndromes. Pediatrics 2008; 122: 139–148.
- 13Alter BP. Diagnosis, genetics, and management of inherited bone marrow failure syndromes. Hematology Am Soc Hematol Educ Program. 2007: 29–39.
- 14Tönnies H, Huber S, Kuhl JS, Gerlach A, Ebell W, Neitzel H. Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: gains of the chromosomal segment 3q26q29 as an adverse risk factor. Blood. 2003; 101: 3872–3874.
- 15Butturini A, Gale RP, Verlander PC, Adler-Brecher B, Gillio AP, Auerbach AD. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood. 1994; 84: 1650–1655.
- 16Alter BP, Giri N, Savage SA, et al. Malignancies and survival patterns in the national cancer institute inherited bone marrow failure syndromes cohort study. Br J Haematol. 2010; 150(2): 179–188.
- 17Mandel K, Dror Y, Poon A, Freedman M. A practical, comprehensive classification for pediatric myelodysplastic syndromes: the CCC system. J Pediatr Hematol Oncol. 2002; 24: 596–605.
- 18Tischkowitz MD, Chisholm J, Gaze M, Michalski A, Rosser EM. Medulloblastoma as a first presentation of Fanconi anemia. J Pediatr Hematol Oncol. 2004; 26(1): 52–55.
- 19Rochowski A, Rosenberg PS, Alonzo TA, Gerbing RB, Lange BJ, Alter BP. Estimation of the prevalence of Fanconi anemia among patients with de novo acute myelogenous leukemia who have poor recovery from chemotherapy. Leuk Res. 2012; 36(1): 29–31.
- 20Miraki-Moud F, Anjos-Afonso F, Hodby KA, et al. Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation. Proc Natl Acad Sci USA. 2013: 110(33): 13576–13581.
